Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 115 participants.

Also called NCT01069692

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 115 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01069692
  • EudraCT 2008-006097-15
Other papers using this trial's data
  • Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy Clinical and experimental nephrology, 2014-02 DOI, PubMed 23670305

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Countries
Belgium, Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01069692. Randomized; double masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2010-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients
Acronym
SBR759
Condition
Hyperphosphatemia
Intervention (Drug)
SBR759A
Intervention (Drug)
SBR759A
Intervention (Drug)
SBR759A
Intervention (Drug)
SBR759A
Intervention (Drug)
SBR759A
Lead sponsor
Novartis (class: industry)

Record details

Record id
cardio:ct-nct01069692
Content hash
0948d17a058eb68a70078f1e2dcbd1be731ac7b6760a61af0191182919fc26d4